Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time

TUCSON, Ariz., Feb. 2, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest

About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno^® system and Accelerate PhenoTest^® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-to-participate-in-btig-medtech-digital-health-life-science--diagnostic-tools-conference-on-february-16-2022-at-1000-am-eastern-time-301473773.html

SOURCE Accelerate Diagnostics, Inc.

Company Codes: NASDAQ-SMALL:AXDX